Kestra Medical Technologies (NASDAQ:KMTS) Insider Traci Umberger Sells 30,000 Shares of Stock

Key Points

• Insider sale: Traci Umberger sold 30,000 Kestra Medical Technologies shares for approximately $900,900 at an average price of $30.03, reducing her ownership by 13.28% to 195,825 shares.
• Stock and earnings: KMTS recently traded at $30.61, near its 52-week high of $31.04. The company reported quarterly revenue of $30.97 million but missed EPS expectations, posting a loss of $0.75 per share versus the estimated $0.61 loss.
• Analyst outlook: Analysts have a “Moderate Buy” consensus rating with an average price target of $29.00, although targets range from $30 to $34. Kestra develops the ASSURE wearable cardioverter defibrillator for patients at risk of sudden cardiac arrest.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) insider Traci Umberger sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of $30.03, for a total value of $900,900.00. Following the completion of the sale, the insider owned 195,825 shares of the company's stock, valued at $5,880,624.75. This trade represents a 13.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Kestra Medical Technologies Stock Performance

KMTS stock traded up $0.74 during trading on Thursday, hitting $30.61. 470,598 shares of the company's stock traded hands, compared to its average volume of 351,886. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of -11.46 and a beta of 0.51. Kestra Medical Technologies, Ltd. has a 52 week low of $17.34 and a 52 week high of $31.04. The stock has a fifty day moving average price of $26.59 and a two-hundred day moving average price of $23.76. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.33.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last posted its quarterly earnings results on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The business had revenue of $30.97 million during the quarter. As a group, equities analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on KMTS shares. JPMorgan Chase & Co. began coverage on Kestra Medical Technologies in a research report on Monday, August 10th. They set an "overweight" rating and a $30.00 price objective for the company. Oppenheimer initiated coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They issued a "market perform" rating on the stock. Royal Bank Of Canada set a $30.00 target price on Kestra Medical Technologies in a research note on Tuesday, September 15th. Evercore initiated coverage on shares of Kestra Medical Technologies in a report on Tuesday, October 20th. They set an "outperform" rating and a $34.00 price target for the company. Finally, Weiss Ratings upgraded Kestra Medical Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, September 16th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $29.00.

Institutional Trading of Kestra Medical Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sterling Capital Management LLC boosted its stake in shares of Kestra Medical Technologies by 834.0% during the 3rd quarter. Sterling Capital Management LLC now owns 878 shares of the company's stock worth $25,000 after acquiring an additional 784 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Kestra Medical Technologies during the 3rd quarter worth about $353,000. Quantinno Capital Management LP purchased a new stake in Kestra Medical Technologies during the first quarter valued at about $431,000. California State Teachers Retirement System boosted its holdings in shares of Kestra Medical Technologies by 39.2% in the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company's stock worth $555,000 after buying an additional 7,844 shares during the period. Finally, Spartan Wealth Advisory Services LLC purchased a new position in shares of Kestra Medical Technologies in the first quarter worth approximately $603,000.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient's heart rhythm and deliver a therapeutic shock when clinically necessary.

The company's platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.